血清半胱天冬酶-3水平与恶性大脑中动脉梗死患者早期死亡的关系
本研究纳入恶性大脑中动脉梗死(定义为CT显示大脑中动脉供血区超过50%的缺血性改变且格拉斯哥昏迷量表≤8分)患者,测定发病第1、4、8天的血清半胱天冬酶-3水平。死亡组(n=34)第1、4、8天血清半胱天冬酶-3水平均高于存活组(n=34)。血清半胱天冬酶-3预测30天死亡的曲线下面积为88%(95%CI=78-95%;p<0.001),多因素logistic回归显示其与30天死亡相关(OR=51.25;95%CI=8.30-316.31;p<0.001)。作者结论认为高血清半胱天冬酶-3水平与恶性大脑中动脉梗死患者死亡相关。
要点
- 恶性大脑中动脉梗死死亡组(n=34)第1天血清半胱天冬酶-3水平高于存活组(n=34),p<0.001。
- 血清半胱天冬酶-3预测30天死亡的曲线下面积为88%(95%CI=78-95%;p<0.001)。
- 多因素logistic回归显示血清半胱天冬酶-3水平与30天死亡相关(OR=51.25;95%CI=8.30-316.31;p<0.001)。
- 死亡组第4天(p=0.001)和第8天(p=0.01)血清半胱天冬酶-3水平也高于存活组。
- 恶性大脑中动脉梗死定义为CT显示大脑中动脉供血区超过50%的缺血性改变且格拉斯哥昏迷量表≤8分。
适用人群与场景
- 恶性大脑中动脉梗死患者,定义为CT显示大脑中动脉供血区超过50%的缺血性改变且格拉斯哥昏迷量表≤8分。
诊断标准与关键阈值
- 恶性大脑中动脉梗死诊断标准:CT显示大脑中动脉供血区超过50%的缺血性改变,且格拉斯哥昏迷量表≤8分。
研究设计与关键结果
- 研究纳入恶性大脑中动脉梗死患者,死亡组34例,存活组34例。
- 死亡组第1天血清半胱天冬酶-3水平高于存活组(p<0.001)。
- 死亡组第4天血清半胱天冬酶-3水平高于存活组(p=0.001)。
- 死亡组第8天血清半胱天冬酶-3水平高于存活组(p=0.01)。
- 血清半胱天冬酶-3预测30天死亡的曲线下面积为88%(95%CI=78-95%;p<0.001)。
- 多因素logistic回归显示血清半胱天冬酶-3水平与30天死亡相关(OR=51.25;95%CI=8.30-316.31;p<0.001)。
证据类型、等级与局限
- 证据类型:研究论文(观察性研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为高血清半胱天冬酶-3水平与恶性大脑中动脉梗死患者死亡相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Circulating caspase-3 levels at 24 h of ischemic stroke were found to be associated with poorer functional neurological outcome in a previous study. The aim of this study was to determine whether there is an association between serum caspase-3 levels and early mortality in patients with malignant middle cerebral artery infarction (MMCAI).
METHODS: We included patients with MMCAI defined as computer tomography showing ischemic changes in more than 50% of the middle cerebral artery territory and Glasgow Coma Scale ≤ 8. Serum caspase-3 levels at days 1, 4, and 8 of MMCAI were determined.
RESULTS: Non-surviving MMCAI (n = 34) showed higher serum caspase-3 levels at days 1 (p < 0.001), 4 (p = 0.001), and 8 (p = 0.01) than surviving patients (n = 34). We found that the area under the curve of serum caspase-3 levels for prediction of mortality at 30 days was 88% (95% CI = 78-95%; p < 0.001). Multiple logistic regression showed that serum caspase-3 levels were associated with 30-day mortality (OR = 51.25; 95% CI = 8.30-316.31; p < 0.001).
CONCLUSIONS: The novel and more important findings of our study were that high serum caspase-3 levels were associated with mortality in MMCAI patients.
参考来源
- Lorente L, Martín MM, Pérez-Cejas A, et al. Serum Caspase-3 Levels and Early Mortality of Patients with Malignant Middle Cerebral Artery Infarction. Neurocrit Care. 2019. PMID: 31115825. doi:10.1007/s12028-019-00739-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。